Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00553618 · ClinicalTrials.gov registry record · Phase 2
Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients
A Phase 2 study of Metastatic Melanoma, sponsored by University of Louisville.
- Active
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT00553618: Active Phase 2 study of Metastatic Melanoma, sponsored by University of Louisville.
NCT00553618 is a Phase 2 study of Metastatic Melanoma that is active but no longer recruiting, run by University of Louisville. The registered enrollment target is 160 participants, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (95% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00553618, a Phase 2 study of Metastatic Melanoma, is active but no longer recruiting, sponsored by University of Louisville.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if the combination of the two cancer drugs, Dacarbazine (DTIC) and a low-dose of Proleukin (IL2), would provide a less toxic and more effective treatment for melanoma than currently available treatments for people with high-risk melanoma. Dacarbazine (DTIC) and Proleukin (IL2) are both FDA-approved drugs for the treatment of melanoma.
Conditions Studied
Interventions
- DRUG Proleukin and Dacarbazine
Study Locations (1)
Kentucky
- James Graham Brown Cancer Center - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2007-08 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What the registry record for NCT00553618 still lists
NCT00553618 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (95% higher).
The record links to 1 condition, with Metastatic Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Proleukin and Dacarbazine is the first listed.
NCT00553618 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT00553618 about?
NCT00553618 is a clinical study titled "Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients". The purpose of this study is to see if the combination of the two cancer drugs, Dacarbazine (DTIC) and a low-dose of Proleukin (IL2), would provide a less toxic and more effective treatment for melanoma than currently available treatments for people with high-risk melanoma. Dacarbazine (DTIC) and Pr...
What is the current status of trial NCT00553618?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2007-08. Estimated completion is 2026-08.
What conditions does trial NCT00553618 study?
This clinical trial studies the following conditions: Metastatic Melanoma.
What interventions are being tested in trial NCT00553618?
The interventions under investigation include: Proleukin and Dacarbazine (DRUG).
Who is sponsoring clinical trial NCT00553618?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00553618 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00553618's enrollment target sits among peer trials
160 12th of 91 higher than 79 of 91 other Metastatic Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
RECRUITING · Phase 2
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RECRUITING · Phase 2
-
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
RECRUITING · Phase 2
-
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
RECRUITING · Phase 2
-
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia